EUVIMEDEUVIMED entdecken
Crossref

Integrating Serine and Pyrimidine Biosynthesis into the E-TRIPOD Signature for Enhanced Lung Cancer Screening

Raúl Isea

Innovative Insights in Digital Health · 12.03.2026

DOI: 10.67335/3143-4371.1005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Innovative Insights in Digital Health, online erschienen am 12.03.2026. Verfasst von Raúl Isea.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Early diagnosis of lung adenocarcinoma is a clinical priority to reduce global mortality, driving the development of various transcriptomic signatures. However, most lack a mechanistic axis connecting gene expression with external diagnostic signals.

Objective

To characterize the Extended TRIPOD (E-TRIPOD) model, a five-gene signature (COL11A1, CDC20, PSAT1, LDHA, and UCK2) that integrates structural, proliferative, and metabolic drivers as a biological and theoretical foundation for future e-Nose-based screening.

Methods

We analyzed the GSE19188 dataset and performed cross-validation on TCGA real-world data cohorts (n > 500). Kaplan-Meier survival analysis, functional enrichment in g:Profiler, and metabolic mapping via RSEA and KEGG were used to identify potential volatile byproducts.

Results

The model showed exceptional prognostic power with a Hazard Ratio of 2.1 (P=8.8×10−16). Unlike standard models, E-TRIPOD reveals a mechanistic axis based on the pyrimidine salvage pathway. Here, the synergy of UCK2 and PSAT1 leads to urea accumulation and its degradation into volatile ammonia (NH3), as mapped through KEGG pathways.

Conclusion

These results position E-TRIPOD as a robust biomarker that turns genomics into an actionable diagnostic tool. This synergy establishes a theoretical framework for the development of biophysically grounded electronic nose technologies, setting a new potential standard for non-invasive screening. Keywords: Lung adenocarcinoma, E-TRIPOD, TRIPOD, Pyrimidine Metabolism, Electronic Nose (e-Nose), Volatile Organic Compounds (VOCs)

Zitieren

APA

Isea, R. (2026). Integrating Serine and Pyrimidine Biosynthesis into the E-TRIPOD Signature for Enhanced Lung Cancer Screening. Innovative Insights in Digital Health. https://doi.org/10.67335/3143-4371.1005

Vancouver

Isea R. Integrating Serine and Pyrimidine Biosynthesis into the E-TRIPOD Signature for Enhanced Lung Cancer Screening. Innovative Insights in Digital Health. 2026. doi:10.67335/3143-4371.1005

BibTeX
@article{Isea2026,
  author = {Isea, Raúl},
  title = {Integrating Serine and Pyrimidine Biosynthesis into the E-TRIPOD Signature for Enhanced Lung Cancer Screening},
  journal = {Innovative Insights in Digital Health},
  year = {2026},
  doi = {10.67335/3143-4371.1005}
}
Kostenlos starten →